These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
272 related items for PubMed ID: 9660504
1. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1524-9. PubMed ID: 9660504 [Abstract] [Full Text] [Related]
2. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Kon CH, Occleston NL, Aylward GW, Khaw PT. Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974 [Abstract] [Full Text] [Related]
3. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Webster L, Chignell AH, Limb GA. Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746 [Abstract] [Full Text] [Related]
12. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Quiram PA, Gonzales CR, Hu W, Gupta A, Yoshizumi MO, Kreiger AE, Schwartz SD. Ophthalmology; 2006 Nov; 113(11):2041-7. PubMed ID: 16952397 [Abstract] [Full Text] [Related]
13. Upregulation of RAGE and its ligands in proliferative retinal disease. Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR. Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297 [Abstract] [Full Text] [Related]
14. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy. Roldán-Pallarés M, Rollín R, Mediero A, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R. Mol Vis; 2005 Jul 07; 11():461-71. PubMed ID: 16030497 [Abstract] [Full Text] [Related]
15. Interleukin-6 and matrix metalloproteinase expression in the subretinal fluid during proliferative vitreoretinopathy: correlation with extent, duration of RRD and PVR grade. Symeonidis C, Papakonstantinou E, Androudi S, Tsaousis KT, Tsinopoulos I, Brazitikos P, Karakiulakis G, Diza E, Dimitrakos SA. Cytokine; 2012 Jul 07; 59(1):184-90. PubMed ID: 22579111 [Abstract] [Full Text] [Related]
16. [Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery]. Lleó Pérez A, Campos Fernández R, López Santoveña F, Sánchez Lorente G, Hernández Martínez FJ, Navarro Palop C. Arch Soc Esp Oftalmol; 2000 Nov 07; 75(11):741-750. PubMed ID: 11151263 [Abstract] [Full Text] [Related]
18. [Retinal detachment with anterior proliferative vitreoretinopathy and its surgical treatment]. Liu W, Wang J, Chen H. Zhonghua Yan Ke Za Zhi; 2000 Sep 07; 36(5):351-4. PubMed ID: 11853627 [Abstract] [Full Text] [Related]
19. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Dieudonné SC, La Heij EC, Diederen RM, Kessels AG, Liem AT, Kijlstra A, Hendrikse F. Ophthalmic Res; 2007 Sep 07; 39(3):148-54. PubMed ID: 17534114 [Abstract] [Full Text] [Related]
20. The role of thrombin in proliferative vitreoretinopathy. Bastiaans J, van Meurs JC, Mulder VC, Nagtzaam NM, Smits-te Nijenhuis M, Dufour-van den Goorbergh DC, van Hagen PM, Hooijkaas H, Dik WA. Invest Ophthalmol Vis Sci; 2014 Jul 11; 55(7):4659-66. PubMed ID: 25015355 [Abstract] [Full Text] [Related] Page: [Next] [New Search]